Observational study of patients at Boston Childrens Hospital with type 1 diabetes (T1D) who elected to treat their diabetes with the Medtronic 670 G hybrid closed loop insulin pump.
Outcome study of 90-100 patients with type 1 diabetes who elected to use the Medtronic 670G. Major outcome measure was to assess the percent of patients who were able to successfully continue to use the 670G technology over time. Additional outcome variables included hemoglobin A1c pre and post treatment with the 670G, time in desired glucose range 70-180.
Study Type
OBSERVATIONAL
Enrollment
96
* percent of patients who continue to use Medtronic 670G over time * impact of 670G on glycemic control: hemoglobin A1c, time in range
Boston Childrens Hospital
Boston, Massachusetts, United States
Successful implementation of hybrid closed loop technology
Percent of Type 1 Diabetes patients who were properly trained on the use of the 670G that continue to use Hybrid Closed Loop technology at 0, 6, 12, 18 and 24 months post training.
Time frame: 0-24 months
Impact of hybrid closed loop technology on glycemic control
Assess impact of hybrid closed loop technology on glycemic control by comparing hemoglobin A1c measurements 0-6 months prior to treatment versus 0-6, 6-12, 12-18, 18-24 months post treatment
Time frame: 0-24 months
Assess impact of hybrid closed loop technology on glycemic control by analysis of sensor glucose data.
Compare sensor glucose data: 1) percent time in range (70-180 mg/dl), 2)percent time in auto-mode, 3) percent time sensor usage versus hemoglobin A1c data over time.
Time frame: 0-24 months.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.